Home›Trial›NCT04325828
🔬NCT04325828Phase 2ACTIVE NOT RECRUITING

A Study of Apalutamide Combined With GnRH Agonist in Participants With Androgen Receptor Positive Salivary Gland Carcinoma

Study Summary

The purpose of the study is to evaluate the overall response rate (ORR) of apalutamide in combination with a gonadotropin-releasing hormone (GnRH) agonist in participants with androgen receptor (AR) expressing locally advanced or recurrent/metastatic salivary gland carcinoma (SGC).

Conditions
Salivary Gland Neoplasms
Interventions / Drugs
ApalutamideGnRH Agonist
View on ClinicalTrials.gov ↗
Sponsor
JNJ
Johnson & Johnson
Diversified Pharma
C60/100
Study Details
Enrollment31 participants
Primary Completion—
Lead SponsorJanssen Pharmaceutical K.K.
Data Retrieved2026-04-11 02:55:31.550497+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.